Biocon Q2 FY26 – Massive Profit Surge Despite Moderate Revenue Growth

Biocon delivered a strong performance in the September 2025 quarter, marked by a sharp turnaround in profitability and steady topline growth, supported by improved operational efficiency and margin expansion. • Sales: ↑ 20% YoY to ₹4,296 crore (vs ₹3,590 crore in Sep 2024) • EBIDT: ↑ 22% YoY to ₹835 crore (vs ₹685 crore) • Net Profit: ↑ 486% YoY to ₹133 crore (vs ₹27.1 crore) • EPS: ↑ 585% YoY to ₹0.63 (vs -₹0.13) At a price of ₹385, market cap ₹51,486 crore, and PE 108.5, Biocon has showcased a remarkable rebound in profitability, reflecting operational turnaround and improving efficiency across its biosimilars and generics businesses.